For immediate release
10 July 2024
Webis Holdings plc
("Webis" or the "Group")
Jim Mellon joins the Webis board
Following regulatory approval, the Board of Webis, the global gaming group, is pleased to announce the appointment of Mr James ("Jim") Mellon as a Non-Executive Director of the Group. Jim is a well-known entrepreneur, investor, and author. His interests include biopharma, life sciences, property, mining, and financial services amongst others. Jim is an honorary Fellow of Oriel College, Oxford and holds a master's degree in Politics, Philosophy and Economics from Oxford University. Jim is the beneficial owner of and Chairman of Burnbrae Group Limited.
Ed Comins, Webis' Managing Director, commented:
"I am delighted to welcome Jim to the Board of Webis. His exceptional commercial experience will prove invaluable as we continue to implement our strategy, and we are sure he will make a very positive contribution to the Board."
James ("Jim") Mellon (age 67)
He has held the following directorships and/or partnerships in the past five years:
Current | Past |
Acruity Limited | Binary Group Ltd |
Agronomics Investment Holdings Limited | Binary Investments (Europe) Limited |
Agronomics Limited | Binary Limited |
Albany Management Limited | Biogerontology Research Foundation |
American Federation of Aging Research | Calabrese Holdings Limited |
Big Group Limited | Extreme Opportunities Limited |
Bradda Head International Limited | Fast Forward Innovations Limited |
Bradda Head Limited | Ferrum Limited |
Bradda Head Lithium Limited | Fixed-Odds Capital (Cook Islands) Ltd |
Buck Institute for Research on Aging | Global Glory Investment Limited |
Burnbrae Germany East GmbH | Insilico Medicine Cayman Subco |
Burnbrae Germany Limited | Insilico Medicine Cayman Topco |
Burnbrae Germany Operations GmbH | Insilico Medicine Hong Kong Limited |
Burnbrae Germany West GmbH | Insilico Medicine, Inc. |
Burnbrae Group Limited | Interman (Hong Kong) Limited |
Burnbrae Limited | Plethora Solutions Holdings plc |
Burnbrae Mitte GmbH | Regent Corporate Finance Limited |
Burnbrae Sachsen GmbH | Regent Fund Management (Asia) Limited |
Calabrese Holdings Limited | Regent Fund Management Limited |
Clean Air Capital Limited | Regent Metals Holdings Limited |
Clean Food Group Limited | Shaanxi Red Dragon Resources Ltd |
Compedica Holdings Limited | Speymill Deutsche Immobilien plc |
Condor Gold Plc | Speymill Property Group (UK) Limited |
Good Dog Food Limited | Wielandstrasse 5 Objekt GmbH |
IC Technology (UK) Limited | |
J2 Music Limited | |
Juvenescence Limited | |
LyGenesis, Inc. | |
Mann Bio Pathfinder Limited | |
Mann Bioinvest (BVI) Limited | |
Mann Bioinvest Limited | |
Manx Financial Group plc | |
MediqVentures Limited | |
New Agrarian Company Advisors Limited | |
New Agrarian Company Limited | |
Podenco Global Limited | |
Portage Biotech, Inc | |
Powered Future Limited | |
Regent Pacific Group Limited | |
SABR Holdings Litd | |
SalvaRx Group Limited | |
SalvaRx Group PLC | |
SalvaRx Limited | |
Shellbay Investments Limited | |
Sleepwell Hotels (UK) Limited | |
Sleepwell Hotels Limited | |
The Longevity Forum Limited | |
Titec (BVI) Limited | |
Winter Limited | |
Wolseley Managers Limited | |
Jim Mellon holds 248,204,442 shares in the Group in the name of Burnbrae Limited, representing 63.1% of the issued capital.
Further information on Mr Mellon which required to be disclosed under Schedule Two, paragraph (g) (i)-(viii) of the AIM Rules for Companies is set out in the Appendix.
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR").
For further information:
Webis Holdings plc Tel: 01624 639396
Denham Eke
Beaumont Cornish Limited Tel: 020 7628 3396
Roland Cornish/James Biddle
Appendix: Further disclosure under Schedule Two, paragraph (g) (i)-(viii) of the AIM Rules for Companies
Jim Mellon was a director of Regent Global Fund and Undervalued Assets Greater China Fund Series III, both of which went into voluntary liquidation. These two funds were liquidated with the consent of shareholders as the directors recommended that, due to a decline in the size of the funds, they were uneconomic. There were no unsatisfied creditors.
Bigsave Holdings plc, a company of which Jim Mellon was a director, entered into a voluntary liquidation. There were no unsatisfied creditors.
On 8 April 2003, Regent Pacific Fund, a company of which Jim Mellon was a director, entered into a voluntary liquidation. There were no unsatisfied creditors.
On 9 December 2005, Undervalued Assets Fund - Series One, a company of which Jim Mellon was a director, entered into a voluntary liquidation. There were no unsatisfied creditors.
On 5 February 2008, Asian Opportunity Fund 1998 - Series I, commenced voluntary liquidation pursuant to its Articles and Association. Jim Mellon was a director within the 12 month periods preceding such date. There were no unsatisfied creditors.
On 29 January 2014, Rivington Street Holdings plc, a company of which Jim Mellon was a director, entered into a voluntary liquidation. The creditors were owed approximately £4 million, of which Jim Mellon and his interests were owed £3.8 million.
On 3 September 2015, Speymill plc, a company of which Jim Mellon was a director, entered into a voluntary liquidation and was subsequently dissolved on 6 July 2017. The combined creditors of the Speymill Group were approximately £4.3 million, of which Jim Mellon and his interests were owed £3.9 million.
There was an historic arrest warrant for Jim Mellon, issued by the Seoul South Korea prosecutor's office on 19 December 2000 and subsequently reissued on 14 January 2004. The warrant was due to remain valid and effective until 12 March 2010. The arrest warrant pertains to an alleged involvement in a conspiracy to manipulate the share price of Regent Securities Co., Ltd. Mr Mellon has informed the Company that he absolutely and categorically denies that this allegation has any substance. No evidence was produced against him and no further proceedings have taken place with no further developments in this matter since 2010.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.